Irvine, CA (PRWEB) July 17, 2015
Proove Biosciences, a commercial and research leader in Personalized Medicine, presented data from three new research studies at the annual Society of Biological Psychiatry meeting in May. The conference, designed to highlight groundbreaking developments in “Stress, Emotion, Neurodevelopment, and Psychopathology,” took place over the course of four days at the Fairmont Royal York Hotel in Toronto, Canada. Proove Biosciences presented data from three genetic and mental health studies: (1) Depression and Pain Perception: Study on the Pain Perception in Subjects with Reported history of Depression, (2) Genetics and Bi-polar Disorders: Study on the Role of Genetics in Risk of Bipolar Disorders, and (3) 5HT2a and Mental Health: Multi-center Study to Determine Association of Genetic Polymorphisms and Mental Disorders.
“Our goal is to clarify the contribution of genetic factors to psychiatric disorders,” stated Svetlana Kantorovich Director of Clinical and Scientific Affairs at Proove Biosciences. “By understanding the associations between genetics and common mental health conditions, we will be able to better classify and stratify patients by specific biological pathways in order to guide personalized treatment.”
Depression and Pain Perception: Study on the Pain Perception in Subjects with Reported history of Depression was conducted to determine if any association exists between subjects with history of depression and pain perception. By analyzing the genetic material of 2,092 pain subjects, 1,030 of which with a history of depression, Proove Biosciences discovered that subjects with reported histories of depression were more likely to be associated with high pain perception compared to those with no history of depression - findings that may help clinicians in making decisions regarding the management of depression and pain patients.
The objective of Genetics and Bipolar Disorders: Study on the Role of Genetics in Risk of Bipolar Disorders was to glean the influence of genetics in bipolar disorder and to discover the genes that may play a role in susceptibility to bipolar disorders. By genotyping 120 pain patients, 57 of which have been diagnosed with bipolar affective disorders, researchers at Proove Biosciences were able to extrapolate that the DRD1 -48A>G SNP had significant association with bipolar disorders. Further analysis showed that those with the A/A variation were more associated with bipolar disorders than those with the A/G-G/G variation.
In the study, 5HT2a and Mental Health Disorders: Multicenter Study to Determine Association of Genetic Polymorphisms and Mental Disorders, researchers identified genes that may be associated with mental health disorders by stratifying the DNA of 1,899 patients into two groups - those with and without mental health disorders, as defined by ICD9 diagnosis. Data showed that the 5-HT2a gene has significant association with mental health disorders, with the G/G and A/A variations being more associated with the presence of mental health disorders than the G/A variation.
About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).